31 May 2017

Scancell Holdings PLC

Scancell Holdings PLC (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has conducted a secondary placing of shares to raise £5 million. 

The proceeds will be used to support the company's clinical development pipeline, in particular to initiate clinical development of the first product from the Moditope(R) platform, Modi-1, and to continue to support the pipeline arising from the ImmunoBody(R) platform.  LGB Investments worked closely with the company's broker, Panmure Gordon, to introduce investors to the transaction.

Recent Articles

26 May 2020

BoE: Negative interest rates not ruled out

Andrew Boyle, CEO of LGB & Co. Limited, contributed to an article for Mortgage Introducer Bank of England Governor Andrew Bailey's refusal to rule out the prospect of negative interest rates.


Read more

News & Insights

4 May 2020

Small cap movers: Coronavirus crisis shines a light on small-cap pharma

Ivan Sedgwick, Investments Director at LGB & Co. Limited, contributed to an article for ProActive Investors on small-cap pharmaceutical companies in the Coronavirus limelight.

Read more

News & Insights

30 April 2020

What impact is COVID-19 having on stocks?

Ivan Sedgwick, Director of Investments at LGB & Co, spoke to BLM to find out about the current outlook for the AIM market.


Read more

News & Insights